≥99% HPLCPre-filled pen

GcMAF

Name: GcMAF
Brand: Dripfy
Availability: InStock

What it is?

GcMAF (Gc protein-derived macrophage activating factor) is a highly controversial, investigational protein derived from the vitamin-D-binding protein and discussed in research as a possible macrophage-activating immune signal. It is not an approved therapy, has been the subject of regulatory warnings, and has no established clinical benefit.

Dripfy Advantage

Macrophage signalling: discussed for a proposed role in activating macrophages (innate immune cells)
Protein origin: derived from a deglycosylated form of the Gc protein (vitamin-D-binding protein)
Immune-modulation concept: positioned only as an experimental, investigational immune-signalling protein used under physician supervision
Honest framing: presented with an explicit caveat — no established clinical benefit and subject of regulatory warnings

Research & Investigational Focus

Immune signalling: claimed in disputed and partly retracted literature to influence macrophage activity — claims not substantiated
Contested research: examined only in preliminary, controversial research contexts
No validated outcomes: explored conceptually within immune-modulation research, without reliable results

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€1,248

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

GcMAF

Gc protein-derived macrophage activating factor (controversial; investigational) · Pre-filled pen

D· Preliminary evidence

GcMAF is proposed to be a deglycosylated form of the vitamin-D-binding protein that, in theory, activates macrophages within the innate immune system. This mechanism is described mainly in disputed and partly retracted literature and has not been reproducibly validated. No robust, credible human trials establish any clinical effect.

Studied use areas

Investigated, in contested research, for macrophage-activation immune signalling
Explored conceptually as an experimental immune-modulating research protein
Subject of preliminary claims that remain unverified and disputed

Safety & status

Highly controversial and NOT an approved therapy; subject of regulatory warnings
No established clinical benefit and no reliable human safety data
Use only under qualified physician supervision; not a treatment for any disease and not for use in pregnancy or breastfeeding

⚕ Clinical note: GcMAF is a highly controversial, investigational protein with no established clinical benefit and a history of regulatory warnings. It is not an approved medicine, is discussed only in a research and physician-directed context, and nothing here is medical advice, a therapeutic claim, or a dosing guide.

Evidence: Grade D — no credible human data; investigational and disputed · References: Yamamoto et al., Cancer Immunology, Immunotherapy 2008 (paper subsequently retracted); Ugarte et al., critical review of GcMAF claims, 2014; MHRA (UK) regulatory statement on unlicensed GcMAF products, 2015